Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span

In the paper

“The use of a navitoclax PROTAC facilitated the rapid and specific degradation of BCL-2, resulting in apoptosis of cancer cells with less off-target lysis.”

What the sources say

• Disputed

  The Discussion states that DT2216, the PROTAC derived from navitoclax, is specific for BCL-XL and does not induce BCL-2 degradation. The Abstract supports reduced platelet toxicity and antitumor activity, but explicitly says DT2216 does not degrade BCL-2—the central target named in the claim. (LLM, conf=0.94)

  Checked by a reasoning model — may be wrong.

  cites [76] sourceExperimental — accuracy not yet measured

In the paper

“Old age is the greatest risk factor for the chronic diseases responsible for the majority of morbidity, mortality, and health-care costs worldwide (1, 2).”

What the sources say

• Partly supported

  The Abstract calls aging the greatest risk factor for a majority of chronic diseases driving morbidity and mortality. The Aging Research Initiative says chronic diseases account for the majority of global disease burden and are the most common causes of mortality. It calls them a major global healthcare burden, but does not establish that they account for the majority of healthcare costs worldwide. (LLM, conf=0.86)

  cites [1] sourceExperimental — accuracy not yet measured
• Partly supported

  The indexed Abstract (page not provided) calls aging the primary risk factor for major human pathologies, including cancer, diabetes, cardiovascular disorders, and neurodegenerative diseases. It does not say that these diseases account for the majority of morbidity, mortality, and health-care costs worldwide. (LLM, conf=0.88)

  cites [2] sourceExperimental — accuracy not yet measured

In the paper

“Fisetin reduces senescence in aged nonhuman primates and human tissue explants (26).”

What the sources say

• Partly supported

  The Results report reduced senescence markers in human adipose tissue explants treated with fisetin. The animal experiments described in the Abstract (Methods) and Results used aged mice, not aged nonhuman primates, so the primate part of the claim is unsupported. (LLM, conf=0.91)

  cites [26] sourceExperimental — accuracy not yet measured

In the paper

“Currently, it is accepted that there is not one single biomarker of Sncs (Figure 2) and that only through the simultaneous measure of multiple end points can Sncs be identified accurately (30).”

What the sources say

• Supported

  The in vivo identification section states that no single marker has absolute specificity for senescent cells and advises a multi-marker approach for more robust detection. The Figure 3 workflow specifies co-staining with additional markers and says the multi-marker workflow can identify senescent cells with the highest accuracy. (LLM, conf=0.94)

  cites [30] source

In the paper

“Inhibitors of these prosurvival proteins, often using repurposed cancer chemotherapeutics, kill Sncs (senolysis), leading to the creation of the first senolytic drugs (19).”

What the sources say

• Partly supported

  The Discussion (page not provided) calls dasatinib and quercetin prototype senolytic agents and says targeting pro-survival mechanisms selectively clears senescent cells. The Results, “Candidate senolytic drugs in vitro” (page not provided), identifies dasatinib as a cancer treatment but quercetin as a natural flavonol; it does not establish that repurposed cancer chemotherapeutics are often used for this purpose. (LLM, conf=0.86)

  cites [19] sourceExperimental — accuracy not yet measured

In the paper

“Rapamycin, an immunosuppressant, decreases the SASP and maintains cell cycle arrest but does not kill Sncs (24).”

What the sources say

• Supported

  The Results sections “Rapamycin decreases the SASP” and “Rapamycin does not reverse cellular senescence” report that rapamycin selectively reduced SASP factors without reversing growth arrest in the primary human cells tested. Senescent-cell numbers were unchanged after treatment, supporting the statement that rapamycin did not kill those cells. (LLM, conf=0.91)

  cites [24] source

In the paper

“Fisetin extends the health span and life span of mice and reverses tissue damage when administered to aged animals (26).”

What the sources say

• Partly supported

  The Discussion reports improved healthspan and extended lifespan in mice treated late in life. The Results report reduced age-related pathology and improved tissue homeostasis in aged mice, but compare treated mice with controls rather than demonstrating that pre-existing tissue damage was reversed. (LLM, conf=0.84)

  cites [26] sourceExperimental — accuracy not yet measured

In the paper

“Clearance of Sncs in INK-ATTAC or p16-3MR mice restores vascular reactivity (12), stabilizes atherosclerotic plaques (13), improves pulmonary function (14), alleviates osteoarthritis (10), improves fatty liver disease (15), improves lung function in a pulmonary fibrosis model (14), and prevents age-related bone loss (16).”

What the sources say

• Supported

  This source is cited for the vascular-reactivity clause, not the other conditions, which have separate citations. In the age-related vascular pathology section (page unavailable), the paper reports improved carotid-artery relaxation after senescent-cell clearance and similar effects following genetic clearance in INK-ATTAC mice. (LLM, conf=0.91)

  cites [12] sourceExperimental — accuracy not yet measured
• Partly supported

  For citation (13), the paper reports that clearing senescent cells in mice improved fibrous-cap thickness, collagen content, and other surrogate markers of plaque stability (section labeled Abstract; page not provided). It concludes that these results strongly suggest greater plaque stability, but it does not establish plaque stabilization through observed rupture outcomes. The other conditions in the sentence are attached to different citations and are not assessed here. (LLM, conf=0.84)

  cites [13] sourceExperimental — accuracy not yet measured
• Supported

  The Abstract and Discussion report that genetic clearance of p16-positive cells in Ink-Attac mice improved pulmonary function after bleomycin-induced lung injury. This supports the pulmonary-function and pulmonary-fibrosis-model claims attached to citation (14); the other conditions in the sentence have separate citations. (LLM, conf=0.92)

  cites [14] sourceExperimental — accuracy not yet measured
• Supported

  The citation to this paper is attached to the fatty-liver claim, not the other listed conditions. In Results, “Senescent cell clearance decreases liver fat accumulation,” the paper reports that AP-induced elimination of senescent cells in INK-ATTAC mice significantly reduced hepatic fat deposition in aged mice and mice fed a high-fat diet. (LLM, conf=0.93)

  cites [15] sourceExperimental — accuracy not yet measured
• Supported

  The citation to this paper is attached specifically to the claim that senescent-cell clearance prevents age-related bone loss, not to the other conditions listed. The paper’s Abstract reports that genetic clearance using INK-ATTAC in old mice with established bone loss improved bone mass, strength, and microarchitecture relative to controls. (LLM, conf=0.93)

  cites [16] sourceExperimental — accuracy not yet measured

In the paper

“In addition, a peptide that blocks the interaction of p53 with FOXO4 (a forkhead transcription factor family member that binds p53 to induce cellular senescence) induces apoptosis of Sncs in vitro and in vivo, improving fitness, hair growth, and renal function in progeroid and aged mice (29).”

What the sources say

• Supported

  The Results report that FOXO4-DRI competes with FOXO4 for p53 binding and induces caspase-dependent apoptosis in senescent cells in vitro. The in vivo Results report reduced senescence and improved fur density, activity or responsiveness, and renal function in fast-aging and naturally aged mice; apoptosis was also observed in treated aged kidney slices ex vivo. Page numbers were not available in our copy. (LLM, conf=0.88)

  cites [29] source

In the paper

“Treating mice with navitoclax reduces Snc burden, alleviates radiation-induced hematopoietic stem cell dysfunction (28), and improves osteoarthritis (10).”

What the sources say

• Supported

  The paper’s Abstract (page unavailable) reports that ABT263 cleared senescent cells in mice and improved the function of irradiated hematopoietic stem cells. The osteoarthritis statement has a separate citation (10) in the citing sentence, so it is not attributed to this paper. (LLM, conf=0.92)

  cites [28] source
• Partly supported

  The paper’s osteoarthritis results (Fig. 2 and Supplementary Fig. 3; page unavailable) report reduced senescent cells, pain, and cartilage erosion in mice treated with UBX0101. The Online Methods list UBX0101, ganciclovir, and AP20187 as treatments, not navitoclax, so this source does not support attributing the osteoarthritis improvement to navitoclax. The radiation-induced stem-cell claim is attached to citation (28), not this source’s citation (10). (LLM, conf=0.86)

  cites [10] sourceExperimental — accuracy not yet measured

In the paper

“Sncs are heterogeneous for several reasons. First, senescence is a dynamic, not static, process. Thus, it is reasonable to assume that within a tissue both early and late Sncs coexist and have distinct phenotypes. Second, Sncs have different expression profiles based on their cell lineage as well as the type of stress that triggered senescence (31). Finally, Sncs play different roles depending on”

What the sources say

• Supported

  Citation (31) is attached to the claim that expression profiles differ by cell lineage and senescence-inducing stress. The Abstract reports transcriptome signatures specific to senescent cell types and inducing stresses; the Results and Discussion also describes cell-type-dependent gene expression. The surrounding claims about timing and physiological roles are not attached to this citation. (LLM, conf=0.94)

  cites [31] source

In the paper

“D+Q also reduces aortic calcification of atherosclerotic ApoE−/− mice (12), improves lung function in a murine model of idiopathic pulmonary fibrosis (14), reduces hepatic steatosis (15), and prevents age-related bone loss (16).”

What the sources say

• Supported

  The citation to this paper (12) supports only the aortic-calcification clause; the other outcomes have separate citations. In “Can chronic senolytic treatment improve hypercholesterolemia-induced vascular pathology?” the paper identifies the mice as ApoE−/− and reports significantly less intimal plaque calcification with D+Q than with vehicle (Fig. 2I). (LLM, conf=0.95)

  cites [12] source
• Supported

  The Results section (‘Senescent cell clearance mitigates fibrotic lung disease’) reports that dasatinib plus quercetin diminished impaired airway function and reduced the loss of lung compliance in bleomycin-injured mice. The paper identifies bleomycin-induced lung injury as its mouse model of idiopathic pulmonary fibrosis. The other effects in the citing sentence have separate citations and are not attributed to this source. (LLM, conf=0.94)

  cites [14] source
• Supported

  Citation (15) supports only the hepatic-steatosis part of the sentence. In Results, “Senescent cell clearance decreases liver fat accumulation,” the paper reports a significant reduction in hepatic fat deposition after D+Q treatment in aged mice and reduced liver fat accumulation in diabetic db/db mice. (LLM, conf=0.94)

  cites [15] source
• Supported

  Citation (16) is attached specifically to the age-related bone-loss claim, not to the preceding claims about aortic calcification, lung function, or hepatic steatosis. In the supplied Abstract passages, monthly D+Q treatment of old mice improved trabecular bone microarchitecture, cortical thickness, and bone strength relative to vehicle. (LLM, conf=0.93)

  cites [16] source

In the paper

“Several senolytics target prosurvival pathways, including the BCL-2/BCL-xL, p53/p21, and PI3K/AKT, and the antiapoptotic pathways, including serpins.”

What the sources say

• Partly supported

  The Results (Senolytic siRNAs) identify BCL-xL, p21, PI3KCD and the serpin PAI-2 as senolytic targets; the Results (Candidate senolytic drugs in vitro) describe quercetin as inhibiting PI3K and serpins. But the Discussion proposes p53 and AKT as targets for future senolytics rather than showing that tested senolytics target them, and these passages do not establish BCL-2 as a target. Page numbers are not available in our copy. (LLM, conf=0.85)

  cites [19] sourceExperimental — accuracy not yet measured

In the paper

“Note that Sncs are not always pathological. They play important roles in, for example, wound healing and parturition (23).”

What the sources say

• Partly supported

  The Introduction and Discussion (page unavailable) report that senescent cells promote cutaneous wound healing, supporting the point that they are not always harmful. Our copy does not address a role in parturition (searched: parturition, childbirth), so that example is unsupported by this source. (LLM, conf=0.88)

  cites [23] sourceExperimental — accuracy not yet measured

In the paper

“A key study demonstrating that caloric restriction, which increases health span and life span, decreases the accumulation of Sncs (18)”

What the sources say

• Partly supported

  In “Caloric restriction retards p16 INK4a accumulation” (page not provided), the paper reports that caloric restriction abolished an age-related increase in a senescence marker in mouse and rat kidneys. It also reduced age-related Ink4a/Arf expression in some tissues, but not others. The study measured markers rather than directly counting senescent cells, so it does not establish a general decrease in their accumulation. (LLM, conf=0.88)

  cites [18] sourceExperimental — accuracy not yet measured

In the paper

“Ablating p16+ cells in these mice suppresses age-related disease, extending the health span of two independent strains of transgenic mice: INK-ATTAC and p16-3MR (see Supplemental Figure 1 for a description of the models) (8–10).”

What the sources say

• Partly supported

  The main text reports that clearing p16-positive cells delayed selected age-related deficits and preserved function in BubR1 progeroid mice carrying INK-ATTAC. Its two tested transgenic lines were INK-ATTAC-3 and INK-ATTAC-5, not INK-ATTAC and p16-3MR; our copy does not report a p16-3MR experiment. No page number is available in the indexed copy. (LLM, conf=0.90)

  cites [8] sourceExperimental — accuracy not yet measured
• Partly supported

  The Abstract and “p16 Ink4a-positive cells shorten lifespan and healthspan” report that clearing p16-positive cells in INK-ATTAC mice extended median lifespan and attenuated age-related deterioration. The two cohorts had different genetic backgrounds, but both used ATTAC; the paper mentions p16-3MR in cell-culture and model-comparison material, not as a second mouse model in which it demonstrated these healthspan effects. Page numbers were not provided for these passages. (LLM, conf=0.90)

  cites [9] sourceExperimental — accuracy not yet measured
• Partly supported

  The main text (Fig. 3a–c) reports that clearing p16-positive cells in INK-ATTAC mice reduced age-related cartilage degeneration. It also reports reduced post-traumatic osteoarthritis symptoms in p16-3MR mice (Fig. 1), but does not show extended health span in both strains; its statement about increased healthy lifespan cites earlier work. (LLM, conf=0.88)

  cites [10] sourceExperimental — accuracy not yet measured

In the paper

“Senomorphics are aimed largely at suppressing the SASP and thereby inflammation.”

What the sources say

• Partly supported

  The Discussion defines senomorphics as compounds that suppress senescent phenotypes, and the Introduction identifies the SASP as including pro-inflammatory factors. But the paper does not say that suppressing the SASP—and thereby inflammation—is the main aim of senomorphics; it describes their action more broadly. (LLM, conf=0.84)

  cites [20] sourceExperimental — accuracy not yet measured

In the paper

“Senolytics do clear postmitotic cells with senescent features, resulting in beneficial health outcomes (16, 34, 35) and reinforcing Sncs’ role in causing disease.”

What the sources say

• Supported

  The paper describes terminally differentiated, non-dividing cells as capable of senescence and reports that senolytic D+Q treatment reduced the percentage of senescent osteocytes in old mice (main text, indexed under Abstract; no page supplied). It also reports improved bone outcomes and concludes that senescent cells play a causal role in age-related bone loss in mice. The demonstrated health benefit and causal finding are specific to bone loss in mice. (LLM, conf=0.90)

  cites [16] source
• Partly supported

  The Introduction and Discussion report that clearing senescent cells in obese mice alleviated impaired neurogenesis and anxiety-like behavior, supporting a disease-contributing role for those cells. But the paper identifies the affected cells as senescent glia, not specifically as postmitotic cells; the Results also say treatment did not alter the frequency of mature neurons. Thus the postmitotic-cell part of the claim is not established by this source. (LLM, conf=0.84)

  cites [34] sourceExperimental — accuracy not yet measured
• Supported

  The Results section, “Senescent-cell clearance reduces cardiac hypertrophy and fibrosis,” reports that the senolytic navitoclax selectively killed senescent cardiomyocytes in vitro and reduced hypertrophy and fibrosis in aged mice. The Discussion describes post-mitotic cardiomyocyte senescence as an effector of myocardial ageing. These findings support the cited sentence as an example involving post-mitotic cells; the reported benefit is improved cardiac-ageing features, not a significant improvement in measured cardiac function. (LLM, conf=0.86)

  cites [35] source

In the paper

“Dasatinib plus quercetin (D+Q) extends health span and life span in aged mice (17), improving cardiovascular function and treadmill endurance, while decreasing frailty, neurologic dysfunction, and bone loss in mice (19).”

What the sources say

• Supported

  The Abstract states that senolytics enhanced remaining health- and lifespan in old mice. The Results section on aged mice reports improved physical function after D+Q treatment and a 36% higher median post-treatment lifespan. The cardiovascular, frailty, neurologic, and bone-loss claims are attached to a different citation in the printed sentence and are not judged here. (LLM, conf=0.93)

  cites [17] source
• Supported

  The Results report improved cardiovascular function in 24-month-old mice, greater treadmill endurance in irradiated mice, and reduced frailty and neurologic symptoms with improved bone parameters in progeroid mice (pages not provided). The life-span statement is attached to citation (17), not this source’s citation (19). (LLM, conf=0.91)

  cites [19] source

In the paper

“Genetic clearance of p16-expressing Sncs from old INK-ATTAC mice results in a 46% reduction in senescent osteocytes, as assessed by measuring SADS, and significantly improves trabecular bone, thicker cortices, and bone strength in the spine and femur (16).”

What the sources say

• Supported

  The paper’s account of the INK-ATTAC experiment reports 46% fewer SADS-positive senescent osteocytes after AP20187 treatment. It also reports better trabecular bone microarchitecture at the spine and femur, significantly greater femoral cortical thickness and strength, and significantly better vertebral biomechanical properties. The copy provides no page number for these passages. (LLM, conf=0.91)

  cites [16] source

In the paper

“and hepatocellular carcinoma (65).”

What the sources say

• Partly supported

  The Abstract and Discussion link chronic liver inflammation and neutrophil-driven damage to hepatocellular carcinoma. The Discussion also mentions increased cellular senescence in the liver, but the paper does not establish that a senescence-associated secretory phenotype (SASP) drives the inflammation or spreads senescence among hepatocytes. Page numbers are unavailable in our copy. (LLM, conf=0.84)

  cites [65] sourceExperimental — accuracy not yet measured

In the paper

“Sncs contribute to chemoattraction of immune cells to visceral adipose tissue in obesity, further contributing to insulin resistance and risk of diabetes (41).”

What the sources say

• Supported

  The Cellular senescence section states that senescent cells attract macrophages to visceral adipose tissue in obesity and can directly cause insulin resistance. The same section links increased senescent-cell burden to type 2 diabetes risk. Page numbers were not supplied in our copy. (LLM, conf=0.93)

  cites [41] source

In the paper

“Interventions that reduce Snc burden can dramatically attenuate arterial calcification, improve endothelial function and nitric oxide signaling (12), and improve survival after major cardiovascular insults”

What the sources say

• Supported

  The Abstract reports improved vasomotor function and nitric oxide responses after senolytic treatment in aged and hypercholesterolemic mice. It reports significantly reduced calcification in hypercholesterolemic mice, while calcification in aged mice only tended to decline. The survival phrase follows citation (12) and is not attributed to this source. (LLM, conf=0.90)

  cites [12] source

In the paper

“Expression of SASP factors, as measured by quantitative polymerase chain reaction (qPCR), is significantly increased in osteocytes but not in osteoblast progenitors or osteoblasts (45).”

What the sources say

• Supported

  The Results report rt-qPCR measurements of SASP genes in the cell populations. In old versus young mice, 23 of 36 genes were significantly higher in osteocytes, while relatively few changed significantly in osteoblast progenitors or osteoblasts; the latter groups showed no significant overall gene-set change. The claim accurately summarizes that contrast. (LLM, conf=0.91)

  cites [45] source

In the paper

“Activin A, a transforming growth factor-β (TGF-β) family member that is a component of the senescent adipocyte progenitor SASP (11), is increased in obese mice and correlates with levels of p16Ink4a.”

What the sources say

• Supported

  The citation (11) is attached to the description of activin A as a TGF-β-family member and a component of the senescent fat-progenitor secretory phenotype, not to the subsequent statement about obese mice or p16Ink4a. The Introduction and Results (pages not specified in our copy) identify activin A as a transforming growth factor superfamily member secreted by senescent fat progenitors and discuss it among candidate SASP factors. (LLM, conf=0.92)

  cites [11] source

In the paper

“Telomere dysfunction, a major driver of hepatocyte senescence, impairs liver regeneration and induces liver cirrhosis in mice (63).”

What the sources say

• ?Could not verify

  The Abstract and “Liver degeneration in NEMO/IKKγ-deficient embryos” section describe embryonic liver apoptosis following NEMO/IKKγ deficiency. Searches for telomere dysfunction, hepatocyte senescence, liver regeneration, and cirrhosis found no passage in our copy addressing the attributed claim. (LLM, conf=0.76)

  cites [63] Rudolph D, 2000, Genes Dev sourceExperimental — accuracy not yet measured

In the paper

“Activin A impedes expression of the insulin-sensitizing adipogenic transcription factors peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT-enhancer-binding protein α (C/EBPα), thereby contributing to failed adipogenesis, lipotoxicity, and insulin resistance (11).”

What the sources say

• Partly supported

  The Results section, “Inhibition of activin A rescues impaired adipogenesis due to senescent CM” (page unavailable), reports that neutralizing activin A improves adipogenesis. The Introduction and Discussion report increased PPARγ and C/EBPα expression, reduced lipotoxicity, and improved insulin sensitivity after senescent-cell clearance or JAK inhibition. They do not establish that activin A directly blocks those transcription factors or causes the downstream metabolic effects; the Discussion calls the link from impaired adipogenesis to insulin resistance a speculation and notes other possible mechanisms. (LLM, conf=0.86)

  cites [11] sourceExperimental — accuracy not yet measured

In the paper

“chronic inflammation driven by the SASP spreads hepatocyte senescence, contributing to liver fibrosis (64)”

What the sources say

• Partly supported

  The Results sections on cellular senescence and inflammation in vivo report SASP-associated bystander effects in fibroblast experiments and increased hepatocyte senescence in chronically inflamed mouse livers. The Discussion describes SASP signalling as a way senescence may spread to bystander cells. The paper does not establish that SASP spreads senescence specifically between hepatocytes or that this process contributes to liver fibrosis; the liver outcome it reports is impaired regeneration. (LLM, conf=0.84)

  cites [64] sourceExperimental — accuracy not yet measured

In the paper

“Senolytics reduce adipocyte hypertrophy, increase the ratio of subcutaneous to visceral adipose tissue, decrease HbA1c, improve glucose tolerance, enhance insulin sensitivity, lower circulating inflammatory mediators, and promote adipogenesis in obese mice (34).”

What the sources say

• Partly supported

  The Results section, under “Pharmacological and Pharmacogenetic Senolytic Approaches Reduce Senescent Cell Burden and Alleviate Systemic Inflammation” (page unavailable), reports that senolytic treatment reduced circulating cytokines in obese mice. Our copy does not report reduced adipocyte hypertrophy, a higher subcutaneous-to-visceral fat ratio, lower HbA1c, improved glucose tolerance or insulin sensitivity, or increased adipogenesis; searches for those outcomes returned no supporting passage. (LLM, conf=0.90)

  cites [34] sourceExperimental — accuracy not yet measured

In the paper

“This concept is supported by a study of aged mice demonstrating that pharmacologic inhibition of the JAK pathway, which regulates the SASP in senescent preadipocytes and endothelial cells in vitro, suppresses markers of both adipose tissue and systemic inflammation and improved parameters of muscle strength, endurance, and coordination (39).”

What the sources say

• Supported

  The systemic and adipose inflammation section reports reduced serum cytokines and adipose inflammatory markers after JAK inhibitor treatment in old mice (Fig. 7). The physical-activity section reports improved grip strength, hanging endurance, and coordination (Fig. 8). The Discussion also reports SASP suppression in senescent preadipocytes and endothelial cells in vitro. (LLM, conf=0.94)

  cites [39] source

In the paper

“senescence occurs rapidly when the cells are grown at atmospheric oxygen (O2) as a consequence of unrepaired oxidative DNA damage, which is a physiologically relevant driver of senescence in vivo (72).”

What the sources say

• Partly supported

  The Discussion (page unavailable) says that unrepaired endogenous nuclear DNA damage in Ercc1−/Δ mice causes senescent cells to accumulate more rapidly in vivo, and the Introduction reports increased oxidative DNA damage in those mice. But the cited paper does not establish the claim about rapid senescence in primary DNA-repair-deficient MEFs grown at atmospheric oxygen; searches for MEFs and atmospheric oxygen did not find that result. (LLM, conf=0.87)

  cites [72] sourceExperimental — accuracy not yet measured

In the paper

“The rat closely recapitulates human physiology and pathophysiology and can be used to study aspects of aging, including longevity, senescence-related pathology, and pharmacologic changes with increasing age.”

What the sources say

• Partly supported

  The review’s Abstract presents rats as a model of human aging and describes their use in studying longevity, age-related pathology, and physiological effects of interventions. Its “Similarity to Human Age-Related Pathology” passage also discusses pharmacological interventions, but does not establish that rats closely recapitulate human physiology and pathophysiology or specifically address how pharmacologic responses change with age. (LLM, conf=0.84)

  cites [81] sourceExperimental — accuracy not yet measured

In the paper

“The Ercc1−/Δ mouse has reduced expression of the ERCC1-XPF endonuclease, which is important for multiple types of DNA repair (78).”

What the sources say

• Supported

  Section 4.5 identifies Ercc1−/Δ mice as hypomorphic for ERCC1-XPF, and the Introduction describes mouse models with decreased levels of the complex. The Introduction also says ERCC1-XPF participates in nucleotide excision repair, interstrand-crosslink repair, and repair of some double-strand breaks. No page numbers are available in our copy. (LLM, conf=0.86)

  cites [78] source

In the paper

“navitoclax eliminates only a restricted range of Sncs and is not senolytic against, for example, human adipocyte progenitors, one of the most abundant Snc types in aged humans or in diabetes and obesity (27), and is not senolytic against human astrocytes.”

What the sources say

• Partly supported

  The Discussion (page unavailable) says navitoclax targets a limited range of senescent cell types and is not senolytic against senescent human primary preadipocytes, supporting the claim about adipocyte progenitors. The paper does not report testing human astrocytes, so it does not support that part of the claim. (LLM, conf=0.89)

  cites [27] sourceExperimental — accuracy not yet measured

In the paper

“we and others reported that navitoclax, a BCL-2 family inhibitor, is senolytic in some but not all Snc types (26).”

What the sources say

• Supported

  The Introduction states that navitoclax targets BCL-2 pro-survival pathway members and causes apoptosis in some but not all senescent cell types. It also says navitoclax decreases the abundance of some but not all human and mouse senescent cell types in vitro. (LLM, conf=0.94)

  cites [26] source

In the paper

“Physical function such as gait speed and chair stand time improved in the treated group.”

What the sources say

• Supported

  The Results (Functional and biological measures) report significant improvements in 4-m gait speed and chair-stands after DQ treatment. The Discussion describes the study as a single-arm, open-label pilot conducted at two clinical sites. The claim reports improvement within the treated group, not an effect relative to a control group. (LLM, conf=0.94)

  cites [83] source

In the paper

“Compared with mouse physiology, rat physiology is easier to monitor and in general more similar to that of humans (81).”

What the sources say

• Partly supported

  The Abstract says rats’ larger size makes physiological analyses, catheterization, and repeated blood sampling easier than in mice. Its glucose-clamp table also shows rat values closer to human values than mouse values for the measures listed. Those specific comparisons do not establish the broader claim that rat physiology is generally more similar to human physiology. (LLM, conf=0.82)

  cites [81] sourceExperimental — accuracy not yet measured

In the paper

“Aged wild-type mice and progeroid Ercc1−/Δ mice accumulate Sncs in the same tissues and to the same level (79), making Ercc1−/Δ mice a good model for studying senolysis.”

What the sources say

• Supported

  The Discussion reports that aged wild-type and progeroid Ercc1−/Δ mice develop senescent cells in the same tissues and at similar levels, although accumulation is faster in the progeroid mice. It concludes that Ercc1−/Δ mice offer a rapid model for evaluating senotherapeutics, which supports their use in studying senolysis. (LLM, conf=0.91)

  cites [79] source

In the paper

“SCAPs differ between cell types; for example, senescent adipocyte progenitors do not depend on BCL-2 family proteins, whereas senescent HUVECs depend on BCL-xL, PI3K, and the HIF-1α pathways.”

In the paper

“screening a library of drugs that regulate autophagy identified rapamycin and rapamycin derivatives known as rapalogs as senomorphic and the HSP90 inhibitors geldanamycin and tanespimycin (17-AAG) as senolytic.”

In the paper

“Thus, they are regarded as a logical therapeutic target.”

In the paper

“Senotherapeutics are a new class of drugs that selectively kill Sncs (senolytics) or suppress their disease-causing phenotypes (senomorphics/senostatics).”

In the paper

“Sncs accumulate with age and at anatomical sites of disease.”

In the paper

“Preclinical data indicate that senolytics alleviate disease in numerous organs, improve physical function and resilience, and suppress all causes of mortality, even if administered to the aged.”

In the paper

“Senescent cells (Sncs) often develop a senescence-associated secretory phenotype to prompt immune clearance, which drives chronic sterile inflammation and plays a causal role in aging and age-related diseases.”

In the paper

“In addition, metformin, a drug widely used to treat type 2 diabetes, limits NF-κB activation (25), thereby reducing the SASP.”

What the sources say

• ?Not checked — no full text of the sourcecites [25] source

In the paper

“The SASP also has negative effects on stem cell function, leading to impaired tissue regeneration (Figure 1).”

In the paper

“Sncs are found at anatomical sites of many diseases (see the list in the Supplemental Appendix) and play a causal role in pathology.”

In the paper

“Even a relatively low number of Sncs are sufficient to cause a chronic, sterile inflammation that disrupts tissue homeostasis and reduces resilience to stress, termed inflammaging (Figure 1).”

In the paper

“Importantly, no senotherapeutic approach should interfere with pathways controlling the cell cycle or the mechanisms driving senescence, as this could promote cancer.”

In the paper

“Senolytics and senomorphics do not interfere with Snc generation, allowing Sncs to form as needed to arrest damaged cells.”

In the paper

“Elimination of Sncs also prevents migration of transplanted monocytes into intra-abdominal adipose tissue and reduces the number of macrophages in this tissue.”

In the paper

“Importantly, clearance of Sncs, by either genetic or pharmacologic approaches, restores neurogenesis and significantly decreases obesity-induced anxiety-like behavior.”

In the paper

“This accumulation is associated with increased activity of SA-βgal and expression of PAI-1, p53, and p16INK4a in adipose tissue and contributes to reduced adipogenesis.”

In the paper

“p53 activation, as occurs in senescence, also inhibits adipocyte differentiation, blunts insulin-induced glucose transport, and increases lipolysis in adipocytes, further contributing to both inflammation and insulin resistance.”

In the paper

“Thus, Sncs increase with age in bones of mice and contribute to osteoporosis, suggesting that senolytics might prove useful to treat this disease and prevent the risk of fractures in the elderly.”

In the paper

“Correspondingly, systemic elimination of p16-expressing cells in INK-ATTAC mice, or elimination of Sncs through administration of senolytic drugs, modestly improves measures of physical function in older mice.”

In the paper

“Targeted repression of p16Ink4a, however, restores satellite cell activation in vitro and augments stem cell engraftment and self-renewal in injured tissue in vivo.”

In the paper

“by promoting redifferentiation of local cells to osteoblast-like or synthetic cell phenotypes (62), both of which favor matrix disruption and excess/alternate matrix production and are mechanistic contributors to vascular stiffening, hypertension, and resultant end-organ failure.”

What the sources say

• ?Not checked — no full text of the sourcecites [62] source

In the paper

“In addition, microalbuminuria is decreased and renal podocyte and cardiac diastolic function are improved with senolytic therapy.”

In the paper

“When prosurvival networks instead of single molecules are targeted, specificity for Sncs can be increased, side effect profiles flattened, and off-target effects on non-Sncs reduced.”

In the paper

“All are effective orally and their elimination t½ is less than 4 h (73, 74)”

What the sources say

• ?Not checked — no full text of the sourcecites [73] source
• ?Not checked — no full text of the sourcecites [74] source

In the paper

“The BubR1H/H mice are also progeroid and carry two hypomorphic alleles of the BUB1B gene, which encodes a core component of the mitotic spindle assembly checkpoint (BUBR1) (80).”

What the sources say

• ?Not checked — no full text of the sourcecites [80] source

In the paper

“certain senolytics may be cell-type specific or tissue specific, so it will be important to examine multiple tissue and cell types for effects.”